Search results
Results from the WOW.Com Content Network
Lobular carcinoma in situ (LCIS) is an incidental microscopic finding with characteristic cellular morphology and multifocal tissue patterns. The condition is a laboratory diagnosis and refers to unusual cells in the lobules of the breast . [ 1 ]
Histopathologic types of breast cancer, with relative incidences and prognoses, with "invasive lobular carcinoma" at top right. Invasive lobular carcinoma (ILC) is breast cancer arising from the lobules of the mammary glands. [1]
Invasive carcinoma NST is a diagnosis of exclusion, which means that for the diagnosis to be made all the other specific types must be ruled out. There are several rare sub-types of invasive carcinoma NST including pleomorphic carcinoma , carcinoma with osteoclast-like stromal giant cells , carcinoma with choriocarcinomatous features , and ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Chromogenic in situ hybridization (CISH) is a cytogenetic technique that combines the chromogenic signal detection method of immunohistochemistry (IHC) techniques with in situ hybridization. [ 1 ] [ 2 ] It was developed around the year 2000 as an alternative to fluorescence in situ hybridization (FISH) for detection of HER-2/neu oncogene ...
Spatial transcriptomics, or spatially resolved transcriptomics, is a method that captures positional context of transcriptional activity within intact tissue. [1] The historical precursor to spatial transcriptomics is in situ hybridization, [2] where the modernized omics terminology refers to the measurement of all the mRNA in a cell rather than select RNA targets.
Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. [ 1 ] [ 2 ] DCIS is classified as Stage 0. [ 3 ] It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography .
Most people who take a drug test take a presumptive test, cheaper and faster than other methods of testing. However, it is less accurate and can render false results. The FDA recommends for confirmatory testing to be conducted and the placing of a warning label on the presumptive drug test: "This assay provides only a preliminary result.